Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study -- United States, August 19, 2022-March 31, 2023.

Authors :: Dalton, Alexandra F.
Diallo, Alpha Oumar
Chard, Anna N.
Moulia, Danielle L.
Deputy, Nicholas P.
Fothergill, Amy
Kracalik, Ian
Wegner, Christopher W.
Markus, Tiffanie M.
Pathela, Preeti
Still, William L.
Hawkins, Sam
Mangla, Anil T.
Ravi, Nivedita
Licherdell, Erin
Britton, Amber
Lynfield, Ruth
Sutton, Melissa
Hansen, AmberJean P.
Betancourt, Gabriela S.
Source :: MMWR: Morbidity & Mortality Weekly Report. 5/19/2023, Vol. 72 Issue 20, p553-558. 6p. 3 Charts.
Publication Year :: 2023
Abstract: The article discusses the effectiveness of the JYNNEOS vaccine in preventing monkeypox (mpox) among gay, bisexual, and other men who have sex with men (MSM) and transgender individuals. Topics discussed include the approval of the JYNNEOS vaccine by the Food and Drug Administration (FDA) for the prevention of smallpox and monkeypox, the results of a matched case-control study conducted in 12 U.S. jurisdictions to evaluate the vaccine's effectiveness against monkeypox.

Tools